Cargando…

How I treat my inflammatory bowel disease-patients with thiopurines?

Thiopurines are essential drugs to maintain remission in patients with inflammatory bowel disease (IBD). Thiopurines used in IBD are azathioprine (2.0-2.5 mg/kg), mercaptopurine (1.0-1.5 mg/kg) and thioguanine (0.2-0.3 mg/kg). However, mainly due to numerous adverse events associated with thiopurine...

Descripción completa

Detalles Bibliográficos
Autores principales: Meijer, Berrie, Mulder, Chris JJ, van Bodegraven, Adriaan A, de Boer, Nanne K H
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095571/
https://www.ncbi.nlm.nih.gov/pubmed/27867685
http://dx.doi.org/10.4292/wjgpt.v7.i4.524
_version_ 1782465305286541312
author Meijer, Berrie
Mulder, Chris JJ
van Bodegraven, Adriaan A
de Boer, Nanne K H
author_facet Meijer, Berrie
Mulder, Chris JJ
van Bodegraven, Adriaan A
de Boer, Nanne K H
author_sort Meijer, Berrie
collection PubMed
description Thiopurines are essential drugs to maintain remission in patients with inflammatory bowel disease (IBD). Thiopurines used in IBD are azathioprine (2.0-2.5 mg/kg), mercaptopurine (1.0-1.5 mg/kg) and thioguanine (0.2-0.3 mg/kg). However, mainly due to numerous adverse events associated with thiopurine use, almost 50% of the patients have to discontinue conventional thiopurine treatment. Extensive monitoring and the application of several treatment strategies, such as split-dose administration, co-administration with allopurinol or dose reduction/increase, may increase the chance of successful therapy. With this review, we provide practical information on how thiopurines are initiated and maintained in two thiopurine research centers in The Netherlands. We provide clinical information concerning safety issues, indications and management of therapy that may serve as a guide for the administration of thiopurines in IBD patients in daily practice.
format Online
Article
Text
id pubmed-5095571
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-50955712016-11-19 How I treat my inflammatory bowel disease-patients with thiopurines? Meijer, Berrie Mulder, Chris JJ van Bodegraven, Adriaan A de Boer, Nanne K H World J Gastrointest Pharmacol Ther Minireviews Thiopurines are essential drugs to maintain remission in patients with inflammatory bowel disease (IBD). Thiopurines used in IBD are azathioprine (2.0-2.5 mg/kg), mercaptopurine (1.0-1.5 mg/kg) and thioguanine (0.2-0.3 mg/kg). However, mainly due to numerous adverse events associated with thiopurine use, almost 50% of the patients have to discontinue conventional thiopurine treatment. Extensive monitoring and the application of several treatment strategies, such as split-dose administration, co-administration with allopurinol or dose reduction/increase, may increase the chance of successful therapy. With this review, we provide practical information on how thiopurines are initiated and maintained in two thiopurine research centers in The Netherlands. We provide clinical information concerning safety issues, indications and management of therapy that may serve as a guide for the administration of thiopurines in IBD patients in daily practice. Baishideng Publishing Group Inc 2016-11-06 2016-11-06 /pmc/articles/PMC5095571/ /pubmed/27867685 http://dx.doi.org/10.4292/wjgpt.v7.i4.524 Text en ©The Author(s) 2016. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Minireviews
Meijer, Berrie
Mulder, Chris JJ
van Bodegraven, Adriaan A
de Boer, Nanne K H
How I treat my inflammatory bowel disease-patients with thiopurines?
title How I treat my inflammatory bowel disease-patients with thiopurines?
title_full How I treat my inflammatory bowel disease-patients with thiopurines?
title_fullStr How I treat my inflammatory bowel disease-patients with thiopurines?
title_full_unstemmed How I treat my inflammatory bowel disease-patients with thiopurines?
title_short How I treat my inflammatory bowel disease-patients with thiopurines?
title_sort how i treat my inflammatory bowel disease-patients with thiopurines?
topic Minireviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5095571/
https://www.ncbi.nlm.nih.gov/pubmed/27867685
http://dx.doi.org/10.4292/wjgpt.v7.i4.524
work_keys_str_mv AT meijerberrie howitreatmyinflammatoryboweldiseasepatientswiththiopurines
AT mulderchrisjj howitreatmyinflammatoryboweldiseasepatientswiththiopurines
AT vanbodegravenadriaana howitreatmyinflammatoryboweldiseasepatientswiththiopurines
AT deboernannekh howitreatmyinflammatoryboweldiseasepatientswiththiopurines